Using this model, we tested the therapeutic anti-metastatic potential of AMB, a selective ETAR antagonist approved by the FDA and EMA for the treatment of pulmonary hypertension, or ATN161, highlighting the advantage of these approaches. Here, EDNRA is linked to pulmonary hypertension.